Valuation : Relay Therapeutics, Inc.

Market Cap 4.11B 3.54B 3.32B 3.03B 5.71B 393B 5.73B 39.43B 15.38B 198B 15.44B 15.11B 658B P/E 2026 *
-11.6x
P/E 2027 * -11.6x
Enterprise Value 3.54B 3.05B 2.86B 2.61B 4.92B 339B 4.94B 33.96B 13.25B 171B 13.3B 13.01B 567B EV / Sales 2026 *
448x
EV / Sales 2027 * 222x
Free-Float
91.35%
Yield 2026 *
-
Yield 2027 * -
1 day-3.35%
1 week-3.45%
Current month-0.32%
1 month+2.62%
3 months+35.04%
6 months+82.94%
Current year+121.87%
1 week 18.6
Extreme 18.6
20.77
1 month 18.1
Extreme 18.1
21.27
Current year 7.01
Extreme 7.01
21.27
1 year 3.57
Extreme 3.57
21.27
3 years 1.78
Extreme 1.775
21.27
5 years 1.78
Extreme 1.775
38.15
10 years 1.78
Extreme 1.775
64.37
Manager TitleAgeSince
Chief Executive Officer 52 28/02/2017
Director of Finance/CFO 49 31/03/2018
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 54 03/05/2015
Director/Board Member 66 30/06/2016
Director/Board Member 52 28/02/2017
Date Insider Type Main position Quantity % Market Cap.
25/08/26
SB Investment Advisers (UK) Ltd.
SellCompany -6,000,000 2.7530%
17/08/26 Sell

Chief Executive Officer

-48,199 0.0221%
14/08/26 Sell

Chief Financial Officer

-17,717 0.0081%
Change 5-day change 1-year change 3-year change Capi.($)
-3.35%-3.45%+408.67%+80.65% 4.11B
-0.78%-1.42%+2.49%+22.78% 50.47B
-6.00%-0.75%+442.41%+544.39% 44.56B
-0.24%+0.74%+38.69%+18.02% 43.08B
-1.55%-2.07%+23.08%+81.47% 41.7B
-0.31%-0.83%+16.15%+51.42% 33.21B
-1.79%-3.24%+27.00%+129.56% 16.77B
-0.58%-2.12% - - 16.28B
-0.88%-0.66%+11.60%+27.75% 14.58B
-1.66%-1.25%+78.59%+46.66% 13.92B
Average -1.71%-1.30%+116.52%+111.41% 27.87B
Weighted average by Cap. -1.73%-1.09%+100.62%+132.80%

Financials

2026 *2027 *
Net sales 7.91M 6.82M 6.39M 5.83M 10.99M 756M 11.03M 75.82M 29.58M 382M 29.7M 29.05M 1.27B 16.53M 14.25M 13.36M 12.19M 22.97M 1.58B 23.05M 158M 61.84M 798M 62.08M 60.73M 2.65B
Net income -323M -278M -261M -238M -449M -30.87B -450M -3.1B -1.21B -15.58B -1.21B -1.19B -51.68B -346M -298M -280M -255M -481M -33.1B -483M -3.32B -1.3B -16.71B -1.3B -1.27B -55.4B
Net Debt -571M -492M -461M -421M -793M -54.54B -795M -5.47B -2.13B -27.53B -2.14B -2.1B -91.3B -442M -381M -357M -326M -614M -42.24B -616M -4.24B -1.65B -21.32B -1.66B -1.62B -70.71B
Logo Relay Therapeutics, Inc.
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.
Employees
202
Date Price Change Volume
28/08/26 US$18.77 -3.35% 2,762,903
27/08/26 US$19.42 -0.21% 2,394,437
26/08/26 US$19.46 -5.40% 2,936,819
25/08/26 US$20.57 +4.10% 2,744,194
24/08/26 US$19.76 +1.65% 2,639,387
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
18.77USD
Average target price
27.08USD
Spread / Average Target
+44.26%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RLAY Stock